PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Sodium-Iodide Symporter

Drugs in development · updated 30 October 2026

Sodium-Iodide Symporter: clinical trials and development status

NLM verified identityNot approved in the USNo EMA authorisation

As of 30 October 2026 Sodium-Iodide Symporter is in 4 active clinical trials (recruiting or ongoing, phases I–III) for 13 diseases. The most advanced phase is II.

4Active trials
IIMost advanced phase
13Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Sodium-Iodide Symporter and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Clear-cell metastatic renal cell carcinomaII1NCT07510334
Renal cell carcinomaII1NCT07510334
Anaplastic large-cell lymphomaI2NCT06508463
Mycosis fungoidesI2NCT06508463
T-cell lymphomaI2NCT06508463
Acute myeloid leukemiaI1NCT03017820
B-cell lymphomaI1NCT03017820
Cutaneous T cell lymphomaI1NCT03017820
Endometrial neoplasmI1NCT03120624
Immunoblastic lymphadenopathyI1NCT03017820
Multiple myelomaI1NCT03017820
Myelodysplastic SyndromesI1NCT03017820
Peripheral T-cell lymphomaI1NCT06508463

Everything on Sodium-Iodide Symporter

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch